Clinical presentations, systemic inflammation response and ANDC scores in hospitalized patients with COVID-19
- PMID: 39341876
- PMCID: PMC11438960
- DOI: 10.1038/s41598-024-73001-x
Clinical presentations, systemic inflammation response and ANDC scores in hospitalized patients with COVID-19
Abstract
The association of anosmia/ageusia with a positive severe respiratory syndrome coronavirus 2 (SARS-CoV-2) test is well-established, suggesting these symptoms are reliable indicators of coronavirus disease 2019 (COVID-19) infection. This study investigates the clinical characteristics and systemic inflammatory markers in hospitalized COVID-19 patients in Taiwan, focusing on those with anosmia/ageusia. We conducted a retrospective observational study on 231 hospitalized COVID-19 patients (alpha variant) from April to July 2021. Clinical symptoms, dyspnea grading, and laboratory investigations, including neutrophil-lymphocyte ratios (NLRs), platelet-lymphocyte ratios (PLRs), and ANDC scores (an early warning score), were analyzed. Cough (64.1%), fever (58.9%), and dyspnea (56.3%) were the most common symptoms, while anosmia/ageusia affected 9% of patients. Those with anosmia/ageusia were younger, had lower BMI, lower systemic inflammatory markers, and better ANDC scores than those without these symptoms. Female patients exhibited lower NLR values and ANDC scores compared to male patients (all p < 0.05). Multivariable regression analysis demonstrated significant associations between NLR and CRP and ferritin levels (all p < 0.01), and between PLR and ESR and ferritin levels (p < 0.01). Categorized ANDC scores significantly correlated with the total hospital length of stay (all p < 0.05). Despite ethnic differences in the prevalence of anosmia/ageusia, our study highlights similar clinical presentations and inflammatory profiles to those observed in Western countries. The ANDC score effectively predicted hospital stay duration. These findings suggest that anosmia/ageusia may be associated with less severe disease and a lower inflammatory response, particularly in younger and female patients. The ANDC score can serve as a valuable prognostic tool in assessing the severity and expected hospital stay of COVID-19 patients.
Keywords: Ageusia; Anosmia; COVID-19; Hospitalization; Inflammation.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 20;5:CD013665. doi: 10.1002/14651858.CD013665.pub3. PMID: 33620086 Free PMC article. Updated.
-
Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study.Curr Med Res Opin. 2022 Jun;38(6):901-909. doi: 10.1080/03007995.2022.2042991. Epub 2022 Mar 9. Curr Med Res Opin. 2022. PMID: 35166141 Free PMC article.
-
Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic.Front Immunol. 2025 Mar 27;16:1545181. doi: 10.3389/fimmu.2025.1545181. eCollection 2025. Front Immunol. 2025. PMID: 40213560 Free PMC article.
-
Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study.Lancet Digit Health. 2021 Sep;3(9):e577-e586. doi: 10.1016/S2589-7500(21)00115-1. Epub 2021 Jul 22. Lancet Digit Health. 2021. PMID: 34305035 Free PMC article.
-
Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020.Emerg Infect Dis. 2021 Feb;27(2):385-395. doi: 10.3201/eid2702.203729. Emerg Infect Dis. 2021. PMID: 33496225 Free PMC article. Review.
Cited by
-
Can the Early Warning Score (ANDC) Predict Tocilizumab Efficacy in Patients with COVID-19 Cytokine Storm?Eur J Rheumatol. 2025 Apr 16;12(1):1-6. doi: 10.5152/eurjrheum.2025.24048. Eur J Rheumatol. 2025. PMID: 40377410 Free PMC article.
References
-
- Berlin, D. A., Gulick, R. M. & Martinez, F. J. Severe Covid-19. N. Engl. J. Med.383, 2451–2460. 10.1056/NEJMcp2009575 (2020). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous